Product development partnerships (PDPs) remain the chief developers of innovative, new medical technologies for people suffering with diseases and health threats that are underserved by traditional markets. Beyond their productivity at introducing medical innovations for underserved populations and health crises, PDPs work highly cost-effectively, develop global research capacity, are essential to achieving long-term health targets like the United Nations Sustainable Development Goals, and have made key contributions to the global response to COVID-19.
Since the release of the Keeping the Promise Report in 2021, PDPs have continued to develop and introduce new medical technologies at an impressive rate and low cost, while navigating increased resource and operational challenges resulting from the COVID-19 pandemic. PDPs continue to play an integral role in pandemic response and preparedness, helping to tackle well-established and yet-to-emerge health threats around the world, saving lives and reducing burdens on global health systems.
Updates for 2023
In 2023 updates have been made, including a case study by MMV on partnering to prevent malaria relapse with a single-dose treatment, general facts and figures on PDPs, information about PDPs and pandemic preparedness as well as the cost effectiveness of PDPs. The three updated factsheets can be downloaded below.